Topic: Type 2 spastic paraplegia

Type 2 spastic paraplegia (SPG2) is a rare genetic disorder caused by null mutations in the gene encoding for the proteolipid protein 1, essential for myelin sheath formation around nerve fibers in the central nervous system (CNS). SPG2 manifests as progressive stiffness and weakness in the legs, accompanied by white matter abnormalities and axonal degeneration in the CNS. These myelin abnormalities impair neural communication, impacting motor function, cognition and may contribute to neuropsychological conditions like anxiety. Leriglitazone, a brain-penetrant PPARγ full agonist, has shown